Q-omics provides the consensus-scored FAM153B profile across patient tissues and cancer cell-line models. FAM153B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM153B is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, FAM153B RNA expression shows 12,794 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUAD, and THYM as cancer lineages where FAM153B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM153B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM153B survival associations across molecular data types. FAM153B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM153B RNA expression–survival associations across cancer types. High FAM153B expression shows unfavorable associations in KIRP and LIHC, but favorable associations in ACC, HNSC, CESC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM153B RNA expression.
This table summarizes FAM153B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM153B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM153B shows lower tumor expression in LUAD, UCEC, KIRP, BRCA and LUSC and higher tumor expression in THCA. The LUAD box plot shows higher FAM153B RNA expression in normal versus tumor tissue (log2 FC = −0.251, t-test p < 0.001).
This table shows molecular features associated with FAM153B in patient tissues and cancer cell lines. In patient samples, FAM153B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM153B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
